Scientific Reports (Jan 2022)
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113
- Ikuhiro Yamada,
- Chigusa Morizane,
- Takuji Okusaka,
- Junki Mizusawa,
- Tomoko Kataoka,
- Makoto Ueno,
- Masafumi Ikeda,
- Naohiro Okano,
- Akiko Todaka,
- Satoshi Shimizu,
- Nobumasa Mizuno,
- Mitsugu Sekimoto,
- Kazutoshi Tobimatsu,
- Hironori Yamaguchi,
- Tomohiro Nishina,
- Hirofumi Shirakawa,
- Yasushi Kojima,
- Takamasa Oono,
- Yasuyuki Kawamoto,
- Masayuki Furukawa,
- Tomohisa Iwai,
- Kentaro Sudo,
- Keiya Okamura,
- Tatsuya Yamashita,
- Naoya Kato,
- Kazuhiko Shioji,
- Kyouko Shimizu,
- Toshio Nakagohri,
- Ken Kamata,
- Hiroshi Ishii,
- Junji Furuse,
- JCOG-HBPOG
Affiliations
- Ikuhiro Yamada
- Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research
- Chigusa Morizane
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
- Takuji Okusaka
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
- Junki Mizusawa
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital
- Tomoko Kataoka
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital
- Makoto Ueno
- Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center
- Masafumi Ikeda
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
- Naohiro Okano
- Department of Medical Oncology, Kyorin University Faculty of Medicine
- Akiko Todaka
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center
- Satoshi Shimizu
- Department of Gastroenterology, Saitama Cancer Center
- Nobumasa Mizuno
- Department of Gastroenterology, Aichi Cancer Center Hospital
- Mitsugu Sekimoto
- Department of Surgery, Kansai Medical University Hospital
- Kazutoshi Tobimatsu
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
- Hironori Yamaguchi
- Department of Surgery, Jichi Medical University
- Tomohiro Nishina
- Department of Gastrointestinal Medical Oncology, National Hospital Organization, Shikoku Cancer Center
- Hirofumi Shirakawa
- Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center
- Yasushi Kojima
- Department of Gastroenterology, National Center for Global Health and Medicine
- Takamasa Oono
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
- Yasuyuki Kawamoto
- Division of Cancer Center, Hokkaido University Hospital
- Masayuki Furukawa
- Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center
- Tomohisa Iwai
- Department of Gastroenterology, Kitasato University School of Medicine
- Kentaro Sudo
- Gastrointestinal Medical Oncology, Chiba Cancer Center
- Keiya Okamura
- Department of Bilio-Pancreatology, Sapporo Kousei General Hospital
- Tatsuya Yamashita
- Department of Gastroenterology, Kanazawa University
- Naoya Kato
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Kazuhiko Shioji
- Department of Internal Medicine, Niigata Cancer Center Hospital
- Kyouko Shimizu
- Department of Gastroenterology, Tokyo Women’s Medical University
- Toshio Nakagohri
- Gastroenterological Surgery, Tokai University School of Medicine
- Ken Kamata
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine
- Hiroshi Ishii
- Gastrointestinal Medical Oncology, Chiba Cancer Center
- Junji Furuse
- Department of Medical Oncology, Kyorin University Faculty of Medicine
- JCOG-HBPOG
- DOI
- https://doi.org/10.1038/s41598-021-04550-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
Abstract In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 354 enrolled patients in JCOG1113 were classify into two groups; < 75 (non-elderly) and ≥ 75 years (elderly) group. We investigated the influence of age on the safety analysis, including the incidence of chemotherapeutic adverse events and the efficacy analysis, including OS. There were no remarkable differences in OS between the elderly (n = 60) and the non-elderly groups (n = 294). In the elderly group, median OS was 12.7 and 17.7 months for those who received GC (n = 20) and GS (n = 40), respectively. The prevalence of all-grade adverse events was similar between the elderly and the non-elderly groups. However, among the elderly group, Grade ≥ 3 hematological adverse events were more frequently observed in the GC arm than in the GS arm. The clinical outcomes of combination chemotherapy in elderly patients with advanced BTC were comparable to non-elderly patients. GS may be the more favorable treatment for elderly patients with advanced BTC.
